Outcomes of measurable residual disease in pediatric acute myeloid leukemia pre- and post-hematopoietic stem cell transplant: validation of difference from normal flow cytometry with chimerism studies and Wilms tumor 1 gene expression
In a prospective, multi-center study of children undergoing hematopoietic stem cell transplantation (HSCT) for AML, we compared the efficacy of “Difference from Normal” (ΔN) flow cytometry approach for residual disease detection with assessment of Wilms Tumor 1 (WT-1) gene expression in a setting where the diagnostic specimen was not available. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 19, 2018 Category: Hematology Authors: David A. Jacobsohn, Michael R. Loken, Mingwei Fei, Alexia Adams, Lisa Eidenschink Brodersen, Brent R. Logan, Kwang Woo Ahn, Bronwen E. Shaw, Morris Kletzel, Marie Olszewski, Sana Khan, Soheil Meshinchi, Amy Keating, Andrew Harris, Pierre Teira, Reggie E. Source Type: research

Expression of intracellular reactive oxygen species (ROS) in haematopoietic stem cells (HSCs) correlates with time to neutrophil and platelet engraftment in patients undergoing autologous bone marrow transplantation
Autologous haematopoietic stem cell (HSC) transplantation is a treatment option for a variety of haematological malignancies. Engraftment following HSC transplantation is dependent upon the number and viability of the stem cells in the graft [1, 2]. Cryopreservation of HSCs is commonly used prior to conditioning for transplantation, however the process involved in storage of HSCs is known to reduce the viability and absolute number of CD34+ stem cells [3, 4]. Cell damage and ultimately cell death during the freeze / thawing process occurs in a proportion of HSCs as a result of damage to the plasma membrane and generation o...
Source: Biology of Blood and Marrow Transplantation - June 19, 2018 Category: Hematology Authors: Lijun Bai, Giles Best, Wei Xia, Lyndsay Peters, Kelly Wong, Christopher Ward, Matthew Greenwood Source Type: research

Autologous stem cell transplant for AL amyloidosis patients aged 70 to 75
Immunoglobulin light chain (AL) amyloidosis is a disorder driven by clonal plasma cells or B cells producing amyloidogenic light chain protein that deposits in various organs leading to organ dysfunction. Like multiple myeloma it is more common in the elderly, with a median age at presentation of 64. [1,2] Autologous stem cell transplantation (ASCT)has been utilized in AL amyloidosis for over two decades and although early experience was marred by high rates of early mortality, advances in understanding of high risk features optimized selection criteria and have helped improve safety and efficacy of this therapy. (Source: ...
Source: Biology of Blood and Marrow Transplantation - June 19, 2018 Category: Hematology Authors: M Hasib Sidiqi, Mohammed A. Aljama, Eli Muchtar, Francis K. Buadi, Rahma Warsame, Martha Q. Lacy, Angela Dispenzieri, David Dingli, Nelson Leung, Wilson I. Gonsalves, Prashant Kapoor, Taxiarchis V. Kourelis, William J. Hogan, Shaji K. Kumar, Morie A. Gert Source Type: research

Modified high-dose melphalan and autologous stem cell transplantation for AL amyloidosis: Experience in 334 patients
In immunoglobulin light chain (AL) amyloidosis, amyloid fibril deposits, derived from immunoglobulin light chains produced by a clonal plasma cell dyscrasia, accumulate in extracellular tissues and damage vital organs. High dose melphalan and autologous stem cell transplantation (HDM/SCT) has been shown to induce durable hematologic and clinical remissions in selected patients with AL amyloidosis, and prolongs survival substantially when hematologic remissions are achieved. In order to reduce treatment related complications, a lower dose of melphalan conditioning, hereafter called modified HDM (mHDM), has been utilized for...
Source: Biology of Blood and Marrow Transplantation - June 19, 2018 Category: Hematology Authors: Vina P. Nguyen, Heather Landau, Karen Quillen, Dina Brauneis, Anthony C. Shelton, Lisa Mendelson, Hafsa Rahman, J. Mark Sloan, Shayna Sarosiek, Vaishali Sanchorawala Source Type: research

Primed to Kill: CTV-1 Stimulated Haploidentical Natural Killer Cells for Consolidation of AML
In this issue of Biology of Blood and Marrow Transplantation, Fehniger et al report results of a Phase 1 dose escalation trial of AML patients in first complete remission (CR1) who received a single infusion of haploidentical CTV-1 primed NK cells (henceforth referred to as CNDO-109), preceded by lymphodepleting chemotherapy.1 Twelve elderly AML patients received a single dose of Cyclophosphamide and four doses of Fludarabine followed by 3  × 105/kg, 1 × 106/kg, or 3 × 106/kg CNDO-109 cells. All patients were ineligible for HSCT, but at high-risk of relapse based on predetermined characteristi...
Source: Biology of Blood and Marrow Transplantation - June 19, 2018 Category: Hematology Authors: Erin Doherty, Rayne H Rouce Source Type: research

Long-Term Functional Outcomes following Hematopoietic Stem Cell Transplant for Early Infantile Krabbe Disease
Krabbe disease, also known as globoid leukodystrophy, is a progressive and fatal neurologic disease caused by autosomal recessive mutations in the galactocerebrosidase (GALC) gene, which lead to deficiency of the enzyme galactocerebrosidase. As a result, psychosine and other toxic metabolites accumulate and severe demyelination occurs [1]. In the most severe form, early infantile Krabbe disease (EIKD), patients develop severe irritability, poor feeding and spasticity in the first months of life with subsequent neurodegeneration and death by 2 years of age if untreated. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 19, 2018 Category: Hematology Authors: Heather Allewelt, Mahsa Taskindoust, Jesse Troy, Kristin Page, Susan Wood, Suhag Parikh, Vinod K. Prasad, Joanne Kurtzberg Source Type: research

Dysfunctional bone marrow mesenchymal stem cells in patients with poor graft function after allogeneic hematopoietic stem cell transplantation
Poor graft function (PGF), characterized by pancytopenia, is a severe complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) [1 –3]. However, the exact pathogenesis of PGF remains unclear, and effective treatment options for PGF are limited [1–4]. Murine studies demonstrated that effective hematopoiesis in the bone marrow (BM) depends on the interaction between hematopoietic stem cells (HSCs) and specific BM microenviron ment [5–8]. Therefore, in previous studies, we focused on the quantity and function of HSCs and BM microenvironment elements in PGF patients [9–14]. (Source:...
Source: Biology of Blood and Marrow Transplantation - June 19, 2018 Category: Hematology Authors: Yang Song, Hong-Yan Zhao, Zhong-Shi Lyu, Xie-Na Cao, Min-Min Shi, Qi- Wen, Fei-Fei Tang, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Xiao-Jun Huang, Yuan Kong Source Type: research

"Risk Score for Development of Veno-Occlusive Disease After Allogeneic Hematopoietic Cell Transplant"
Veno-occlusive disease of the liver (VOD) is an uncommon, early complication of hematopoietic cell transplantation (HCT) that is associated with significant mortality [1,2]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 18, 2018 Category: Hematology Authors: Christopher Strouse, Ying Zhang, Mei-Jie Zhang, Alyssa DiGilio, Marcelo Pasquini, Mary M. Horowitz, Stephanie Lee, Vincent Ho, Muthalagu Ramanathan, Wichai Chinratanalab, Alison Loren, Linda J. Burns, Andrew Artz, Kathleen F. Villa, Wael Saber Source Type: research

Gastrointestinal graft-versus-host disease is a risk factor for post-engraftment blood stream infection in allogeneic hematopoietic stem cell transplant recipients
Blood stream infection (BSI) is a common complication in patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and can be fatal without appropriate and expedient treatment, especially in the pre-engraftment period [1 –3]. Intensive chemotherapy and irradiation allows bacteria to enter the systemic circulation via disrupted mucosal barriers of the gastrointestinal (GI)-tract and/or oral cavity, providing an inflammatory cytokine milieu fit for T-cell proliferation and activation, This culminates in the developm ent of acute graft-versus-host disease (GvHD) after the engraftment of donor cells [...
Source: Biology of Blood and Marrow Transplantation - June 15, 2018 Category: Hematology Authors: Yasuo Mori, Goichi Yoshimoto, Ruriko Nishida, Takeshi Sugio, Kohta Miyawaki, Takahiro Shima, Yoji Nagasaki, Noriko Miyake, Yukiko Harada, Yuya Kunisaki, Kenjiro Kamezaki, Akihiko Numata, Koji Kato, Motoaki Shiratsuchi, Takahiro Maeda, Katsuto Takenaka, Hi Source Type: research

Early Fever after Haploidentical BMT Correlates with Class II HLA-Mismatching and Myeloablation but not Outcomes
HLA-haploidentical (haplo) transplantation is being increasingly utilized for the treatment of patients with hematologic malignancies lacking a suitable HLA-matched donor [1-4]. Recently, several groups have reported the occurrence of high fever in the absence of bacteremia, occurring between 1 and 5 days after haplo HSCT [5-10]. For example, noninfectious early fever occurred in 18 of 20 (90%) of recipients of haplo peripheral blood transplantation (PBT) after myeloablative conditioning (MAC) and post-transplant cyclophosphamide (PTCy) [7] and in 38 out of 100 (38%) of patients receiving haplo PBT with conditioning includ...
Source: Biology of Blood and Marrow Transplantation - June 15, 2018 Category: Hematology Authors: Shannon R. McCurdy, Stephen T. Muth, Hua-Ling Tsai, Heather J. Symons, Carol Ann Huff, William H. Matsui, Ivan Borrello, Douglas E. Gladstone, Lode J. Swinnen, Kenneth R. Cooke, Robert A. Brodksy, Javier Bola ños-Meade, Richard F. Ambinder, Ravi Varadhan Source Type: research

TBI: To Be (Irradiated) or not to be? That remains the question
The feasibility and success of allogeneic hematopoietic cell transplantation (HCT) was first reported by Thomas and colleagues over 40 years ago using lethal doses of total body irradiation (TBI) and high dose cyclophosphamide (Cy) to eradicate acute leukemia with subsequent reconstitution of marrow function.1 Although these high doses of TBI may have reduced the risk of relapse,2 it was offset by excessively high treatment-related mortality (TRM) (>50%), with both immediate and long-term post-transplant complications. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 14, 2018 Category: Hematology Authors: Betty Ky Hamilton Source Type: research

Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B-cell Lymphoma Treated with Second-line Therapy and Intent to Transplant
Primary mediastinal (thymic) large B-cell lymphoma (PMBL) is a subtype of diffuse large B-cell lymphoma (DLBCL) with distinct clinical, molecular and genetic features. First identified as a unique entity in 1980 [1, 2], our understanding of PMBL continues to be defined as new biologic insights are applied to the clinical treatment paradigm. PMBL accounts for 6-13% of all DLBCL diagnoses and is recognized in both the Revised European-American Classification of Lymphoid Neoplasms (REAL) and World Health Organization (WHO) classifications as a distinct subtype of DLBCL [3, 4]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 14, 2018 Category: Hematology Authors: Santosha Vardhana, Paul A. Hamlin, Joanna Yang, Andrew Zelenetz, Craig S. Sauter, Matthew J. Matasar, Andy Ni, Joachim Yahalom, Craig H Moskowitz Source Type: research

Hematogones predict better outcome in allogeneic hematopoietic stem cell transplantation irrespective of graft sources
Hematogones are benign precursors of B lymphocytes that are present in bone marrow, with similar morphology and immunophenotype to leukemic lymphoblasts.1 –4 They are usually found in large numbers in bone marrow of infants and young children, but decrease significantly with aging.2,5–9 They are more commonly found in the recovery phase following chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT).1,2,5,7,10–14 It has been suggested that they could reflect recapitulation of B cells. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 14, 2018 Category: Hematology Authors: Takashi Ishio, Junichi Sugita, Takahiro Tateno, Daisuke Hidaka, Eiko Hayase, Souichi Shiratori, Kohei Okada, Hideki Goto, Masahiro Onozawa, Masao Nakagawa, Daigo Hashimoto, Kaoru Kahata, Katsuya Fujimoto, Tomoyuki Endo, Takeshi Kondo, Takanori Teshima Source Type: research

Response to letter to editor for YBBMT-D-18-00212
Response: We thank the authors for their comments, which we addressed in the discussion of our article. We found no evidence of a Nocardia outbreak to explain the increase in nocardial infections, which occurred over a period of several years at multiple locations 1. Furthermore, since the lung is the most common site of nocardial infection in both sporadic cases as well as in reported outbreaks, the occurrence of only pulmonary cases in our report does not necessarily imply that there was a localized outbreak. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 14, 2018 Category: Hematology Authors: Alfonso Molina, Drew J. Winston, Darren Pan, Gary J. Schiller Source Type: research

Higher CD45RA+ Regulatory T Cells in The Graft Improves Outcome in Younger Patients Undergoing T Cell Replete Haploidentical Transplantation: Where Donor Age Matters
Early and aggressive alloreactivity remains one of the major causes of morbidity and mortality following HLA-mismatched allogeneic hematopoietic stem cell transplantation (HSCT). Haploidentical family donor HSCT is emerging as the front-runner for alternate donor transplantation since the introduction of post-transplantation cyclophosphamide (PTCy) [1]. Based on the encouraging results witnessed in adults, we had extended PTCy based haploidentical HSCT to the pediatric age group. We had reported a high incidence of both acute graft-versus host disease (GVHD) [2] and post-transplantation hemophagocytic syndrome (PTHPS) with...
Source: Biology of Blood and Marrow Transplantation - June 13, 2018 Category: Hematology Authors: Sarita Rani Jaiswal, Prakash Bhakuni, Aby Joy, Nisha Murli, Ashok Rajoreya, Aditi Chakrabarti, Suparno Chakrabarti Tags: Original Article Source Type: research

Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: the FOND-O Trial
Over the past two decades, the overall incidence of chemotherapy-induced nausea and vomiting (CINV) has improved with greater insight into physiologic pathways and subsequent novel drug development. Namely, the development of 5-HT3 receptor antagonists in the early 1990 ’s followed by NK-1 receptor antagonist in the early 2000’s significantly improved acute and delayed CINV outcomes [1]. Despite proper implementation of these pharmacologic agents as well as non-pharmacologic methods for prophylaxis, CINV - particularly nausea, remains a clinically significant s ide effect for patients receiving moderately and h...
Source: Biology of Blood and Marrow Transplantation - June 13, 2018 Category: Hematology Authors: Amber B. Clemmons, Julianne Orr, Benjamin Andrick, Arpita Gandhi, Claude Sportes, David DeRemer Source Type: research

Additional cytogenetic abnormalities with Philadelphia chromosome-positive acute lymphoblastic leukemia on allogeneic stem cell transplantation in the tyrosine kinase inhibitor era
Philadelphia chromosome (Ph) is detected in approximately 20 to 30 percent of adult acute lymphoblastic leukemia (ALL) [1 –3]. The long-term outcome on conventional chemotherapy alone is dismal even in patients who achieve complete remission, because of a high relapse rate. Therefore, allogenic hematopoietic stem cell transplantation (HSCT) is the standard consolidation therapy, when feasible [4,5]. Over the last dec ade, tyrosine kinase inhibitor (TKI) has dramatically improved the survival outcome of Ph+ ALL [6–12]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 13, 2018 Category: Hematology Authors: Yu Akahoshi, Shuichi Mizuta, Hiroaki Shimizu, Naoyuki Uchida, Takahiro Fukuda, Heiwa Kanamori, Makoto Onizuka, Yukiyasu Ozawa, Kazuteru Ohashi, Shuichi Ohta, Tetsuya Eto, Junji Tanaka, Yoshiko Atsuta, Shinichi Kako Source Type: research

Haploidentical bone marrow transplantation with post-transplant cyclophosphamide/bendamustine in pediatric and young adult patients with hematologic malignancies
Haploidentical hematopoietic cell transplantation (haplo-HCT) has emerged as a safe and effective treatment for patients with hematologic malignancies. The most widely used approach, particularly in North America, is T-cell replete haplo-HCT with post-transplant cyclophosphamide (PT-CY) [1 –5]. While there have been numerous reports, of haplo-HCT with PT-CY in adults, there have been very limited primarily pediatric publications to date [6–8]. Jaiswal et al. reported on the use of PT-CY following a chemotherapy based myeloablative conditioning (MAC) regimen and unmanipulated perip heral blood hematopoietic cell...
Source: Biology of Blood and Marrow Transplantation - June 13, 2018 Category: Hematology Authors: Emmanuel Katsanis, Lauren N. Sapp, Nicole Varner, Shannon Koza, Baldassarre Stea, Yi Zeng Source Type: research

Salival α-iduronidase activity as a potential new biomarker for the diagnosis and monitoring the effect of therapy in mucopolysaccharidosis i
Mucopolysaccharidosis type I (MPS-I) is an autosomal recessive inherited deficiency of the enzyme α-iduronidase (IDUA; EC 3.2.1.76), which leads to accumulation of glycosaminoglycans within the lysosomes. MPS-I includes a spectrum of clinical phenotypes ranging from mild to severe. Hurler syndrome (MPS-1H) represents the most severe subtype, resulting in progressive and ultimately fatal multisy stem disease.1,2 At present, haematopoietic cell transplantation (HCT), based on the principle of cross-correction, is the only treatment able to prevent deterioration of the central nervous system. (Source: Biology of Blood a...
Source: Biology of Blood and Marrow Transplantation - June 12, 2018 Category: Hematology Authors: Jaap van Doorn, Brigitte T.A. van den Broek, Ans J. Geboers, G é-Ann Kuiper, J.J. Boelens, Peter M. van Hasselt Source Type: research

Utility of Autopsy among Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients: One Last Chance to Learn?
Autopsies may give comfort to the families of deceased patients and provide insight into the clinical circumstances surrounding a patient's death [1 –4]. Families may benefit from autopsy through the recognition that they are helping to further medical knowledge or through reassurance that appropriate medical care was provided [3]. Autopsies may also confirm clinical diagnoses, clarify the cause of death, or identify conditions that were not s uspected by the clinical team prior to the patient's death [5]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 9, 2018 Category: Hematology Authors: Matthew S. Kelly, Lisa Spees, Richard Vinesett, Andre Stokhuyzen, Lauren McGill, Alan D. Proia, Kirsten Jenkins, Mehreen Arshad, Patrick C. Seed, Paul L. Martin Source Type: research

A Mesenchymal Stromal Cell (MSC)-Derived Combination of CXCL5 and Anti-CCL24 is Synergistic and Superior to MSC and Cyclosporine for the Treatment of Graft-Versus-Host Disease
• MSCs regulate immunosuppression via upregulating CXCL5 and downregulating CCL24.• A synergistic two-factor combination (2FC) of CXCL5 and anti-CCL24 ameliorates GVHD.• The 2FC modulates immune reaction via suppression of TH1 and TH17 responses.• It is superior to MSC and cyclosporine for G VHD treatment.• This novel combination could substitute for MSC therapy in GVHD treatment. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 5, 2018 Category: Hematology Authors: Xiubo Fan, Dianyang Guo, Alice M.S. Cheung, Zhi Yong Poon, Chui Sun Yap, Shane Goh Ee, Dianyan Guo, Huihua Li, Sudipto Bari, Shang Li, Kiat Hon Lim, William Hwang Ying Khee Source Type: research

Chromosomal Aberrations and Survival after Unrelated Donor Hematopoietic Stem Cell Transplant in Patients with Fanconi Anemia
• Gains of chromosome 1q and 3q and deletion of 7q or monosomy 7 were the most frequently detected aberrations in pre-HCT blood samples of patients with Fanconi Anemia (FA).• Gains of chromosome 3q, and aberrations in 3 or more chromosomes in patients with FA were associated with poor survival a fter unrelated donor HCT.• Post-HCT survival in patients with deletion of 7q or monosomy 7 was not significantly worse than in patients without those aberrations. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 4, 2018 Category: Hematology Authors: Youjin Wang, Weiyin Zhou, Blanche P. Alter, Tao Wang, Stephen R. Spellman, Michael Haagenson, Meredith Yeager, Stephanie J. Lee, Stephen J. Chanock, Sharon A. Savage, Shahinaz M. Gadalla Source Type: research

Can We Kill Two Birds with This Stone? Anti-Pneumocystis Prophylaxis to Prevent Nocardia Infection in Hematopoietic Stem Cell Transplant Recipients
We read with interest the recent paper by Molina and coworkers, who studied the relationship between anti-Pneumocystis prophylaxis and Nocardia infections in allogeneic hematopoietic stem cell transplant recipients. The authors concluded that the use of atovaquone may be associated with an increased risk of Nocardia infection after allogeneic hematopoietic stem cell transplantation, as compared with cotrimoxazole. In response, we would like to make three comments. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 4, 2018 Category: Hematology Authors: Julien Coussement, Julien De Greef, Am élie Duréault, David Lebeaux Source Type: research

ASBMT Notes
In last month's issue, we covered the general evolution of bone marrow transplantation (BMT) leading up to the formation of the ASBMT. In this issue, we continue the story with insights and reflections from some of the founding members on the very first meeting of ASBMT. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 1, 2018 Category: Hematology Tags: ASBMT Notes Source Type: research

Masthead (Purpose and Scope)
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 1, 2018 Category: Hematology Source Type: research

Editorial Board
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 1, 2018 Category: Hematology Source Type: research

Officers and Directors of ASBMT
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 1, 2018 Category: Hematology Source Type: research

Table of Contents
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 1, 2018 Category: Hematology Source Type: research

Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting
The standard of care for patients with relapsed or refractory classic Hodgkin lymphoma (HL) after front-line treatment is salvage chemotherapy followed by high-dose chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT) [1,2]. Several strategies have been explored to prevent relapse after auto-HSCT, including involved-field radiation, immunotherapy, tandem auto-HSCT, and allogeneic HSCT [3-5]. Given the short- and long-term side effects of previous chemotherapies and high-dose conditioning regimens during HSCT, post-transplant therapies should have manageable safety profiles that do not compromise ...
Source: Biology of Blood and Marrow Transplantation - May 30, 2018 Category: Hematology Authors: Auayporn Nademanee, Anna Sureda, Patrick Stiff, Jerzy Holowiecki, Muneer Abidi, Naomi Hunder Hunder, Michael Pecsok, Mayur Uttarwar, Indra Purevjal, John Sweetenham Source Type: research

Provisional Title: Safety Analysis of Brentuximab Vedotin From the Phase 3 AETHERA Trial in Hodgkin Lymphoma in the Posttransplant Consolidation Setting
• Brentuximab vedotin (BV) is approved for the treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression post-auto-HSCT.• BV-associated peripheral neuropathy is manageable via dose modification and is largely reversible upon treatment cessation.• Understandin g the frequency, severity, and management of BV-associated AEs can help optimize outcomes in patients with HL. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 30, 2018 Category: Hematology Authors: A. Nademanee, A. Sureda, P. Stiff, J. Holowiecki, M. Abidi, N.N. Hunder, M. Pecsok, M. Uttarwar, I. Purevjal, J. Sweetenham Source Type: research

A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: an Observational Study on Patients From Fondazione Italiana Linfomi (Fil).
The first series of patients transplanted with autologous marrow for lymphomas was reported in 1978, using the BACT (Carmustine [BCNU]-Citarabine-Cyclophosphamide-Thioguanine) regimen.1 Many variants were derived from the same chemotherapy backbone, among which the BCNU-Etoposide-Citarabine-Melphalan (BEAM) regimen, first reported in 1986.2 (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 29, 2018 Category: Hematology Authors: Jacopo Olivieri, Federico Mosna, Matteo Pelosini, Angelo Fama, Sara Rattotti, Margherita Giannoccaro, Giuseppe Carli, Maria Chiara Tisi, Simone Ferrero, Nicola Sgherza, Anna Maria Mazzone, Dario Marino, Teresa Calimeri, Giacomo Loseto, Francesco Saraceni, Source Type: research

Novel Ultrasonographic Scoring System of Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation
Sinusoidal obstruction syndrome (SOS), also known as hepatic veno-occlusive disease (VOD), is 1 of the life-threatening complications after hematopoietic stem cell transplantation (HSCT) [1]. Typical clinical presentations of SOS/VOD include body weight gain, painful hepatomegaly, ascites, and jaundice [2,3]. The incidence of SOS/VOD after HSCT varies from 5% to 60% [4-10], depending on types of conditioning regimen and cancer treatments before HSCT. SOS/VOD is induced by damage of the hepatic sinusoidal endothelial cells by cytotoxic agents, such as busulfan, cyclophosphamide, gemtuzumab ozogamicin, and inotuzumab ozogami...
Source: Biology of Blood and Marrow Transplantation - May 24, 2018 Category: Hematology Authors: Mutsumi Nishida, Kaoru Kahata, Eiko Hayase, Akio Shigematsu, Megumi Sato, Yusuke Kudo, Satomi Omotehara, Takahito Iwai, Junichi Sugita, Hitoshi Shibuya, Chikara Shimizu, Takanori Teshima Source Type: research

Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation
• MAC regimens for Haplo-HCT with PTCy were associated with reduced relapse but increased NRM• There were no differences in OS or DFS between RIC and MAC Haplo-HCT patients• Rates of acute and chronic GvHD were not different between our RIC and MAC patients (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 24, 2018 Category: Hematology Authors: Eric Huselton, Michael Slade, Kathryn M. Trinkaus, John F. DiPersio, Peter Westervelt, Rizwan Romee Source Type: research

A Novel Ultrasonographic Scoring System of Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation
• Newly established ultrasound scoring system could efficiently diagnose SOS/VOD.• Appropriate cut off value to detect SOS/VOD was determined.• US scoring system detected a certain SOS/VOD preceded to clinical diagnosis. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 24, 2018 Category: Hematology Authors: Mutsumi Nishida, Kaoru Kahata, Eiko Hayase, Akio Shigematsu, Megumi Sato, Yusuke Kudo, Satomi Omotehara, Takahito Iwai, Junichi Sugita, Hitoshi Shibuya, Chikara Shimizu, Takanori Teshima Source Type: research

Preclinical Canine Model of Graft-versus-Host Disease after In Utero Hematopoietic Cell Transplantation
In utero hematopoietic cell transplantation (IUHCT) is a nonmyeloablative approach capable of achieving allogeneic mixed hematopoietic chimerism and associated donor-specific tolerance (DST) without conditioning under specific experimental circumstances [1]. We previously demonstrated that an optimized approach in the preclinical canine model yields stable and consistent engraftment associated with levels of hematopoietic chimerism sufficient for the uniform induction of DST and that are potentially therapeutic for many hematopoietic disorders [2]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 23, 2018 Category: Hematology Authors: Jesse D. Vrecenak, Erik G. Pearson, Carlyn A. Todorow, Haiying Li, Mark P. Johnson, Alan W. Flake Source Type: research

A Preclinical Canine Model of Graft Versus Host Disease Following in Utero Hematopoietic Cell Transplantation
This study demonstrates a safe therapeutic index for IUHCT (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 23, 2018 Category: Hematology Authors: Jesse D. Vrecenak, Erik G. Pearson, Carlyn A. Todorow, Haiying Li, Mark P. Johnson, Alan W. Flake Source Type: research

Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation
JAK inhibition by ruxolitinib is approved for treating myelofibrosis and also has shown efficacy in treating steroid-resistant acute and chronic graft-versus-host disease (GVHD). In 12 patients with myelofibrosis (median age, 63 years; range, 43 to 71 years) who were treated with ruxolitinib and underwent allogeneic stem cell transplantation (ASCT), ruxolitinib was continued (2 × 5 mg daily) until stable engraftment. No graft failure was observed, and leukocyte engraftment was achieved after a median of 12 days (range, 11 to 18 days). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 22, 2018 Category: Hematology Authors: Nicolaus Kr öger, Sharifah Shahnaz Syed Abd Kadir, Tatjana Zabelina, Anita Badbaran, Maximilian Christopeit, Francis Ayuk, Christine Wolschke Source Type: research

Peritransplant Ruxolitinib Prevents Acute GVHD in Myelofibrosis Patients Undergoing Allogenic Stem Cell Transplantation
JAK inhibition by Ruxolitinib is approved for treatment of myelofibrosis and showed efficacy in steroid resistant acute and chronic graft-versus-host disease (GVHD)In twelve patients with a median age of 63 years (range 43-71) and myelofibrosis who were treated with ruxolitinib and underwent allogeneic stem cell transplantation (ASCT) ruxolitinib was continued (2 x 5mg) daily until stable engraftment.No graft failure was observed and leukocyte engraftment was achieved after a median of 12 days (range 11 - 18) One patient developed fever of unknown origin after discontinuation of ruxolitinib, otherwise no case of withdrawal...
Source: Biology of Blood and Marrow Transplantation - May 22, 2018 Category: Hematology Authors: Nicolaus Kr öger, Sharifah Shahnaz Syed Abd Kadir, Tatjana Zabelina, Anita Badbaran, Maximilian Christopeit, Francis Ayuk, Christine Wolschke Source Type: research

Validation of the Revised Pretransplant Assessment of Mortality Score in Patients with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Counseling of patients with acute myelogenous leukemia (AML) for allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a complex task. This is due to the need to balance the potential curative outcome of allo-HSCT with the accompanying high risk of transplantation-associated morbidity and mortality. Thus, assessing a patient's risk profile is critical for effective counseling. Several scoring systems have been developed to predict outcomes after allo-HSCT. One of the most frequently used tools is the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) [1], which incorporates information ...
Source: Biology of Blood and Marrow Transplantation - May 21, 2018 Category: Hematology Authors: Jan M. Middeke, Frederike Kollinger, Henning Baldauf, Friedrich St ölzel, Martin Wermke, Malte von Bonin, Katja Sockel, Cornelia S. Link, Raphael Teipel, Christoph Röllig, Christian Thiede, Uwe Platzbecker, Gerhard Ehninger, Martin Bornhäuser, Johannes Source Type: research

Validation of the Revised PAM Score in Patients with AML Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
• The revised PAM score allows for simple and valid estimation of transplant outcome• Both the CIR and NRM increased with higher PAM scores• In multivariate analysis, age, disease stage, and the PAM score had a significant impact on OS (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 21, 2018 Category: Hematology Authors: Jan M. Middeke, Frederike Kollinger, Henning Baldauf, Friedrich St ölzel, Martin Wermke, Malte von Bonin, Katja Sockel, Cornelia S. Link, Raphael Teipel, Christoph Röllig, Christian Thiede, Uwe Platzbecker, Gerhard Ehninger, Martin Bornhäuser, Johannes Source Type: research

Single Ultra-High-Dose Cholecalciferol to Prevent Vitamin D Deficiency in Pediatric Hematopoietic Stem Cell Transplantation
Vitamin D is a major contributor to enteral calcium and phosphorus absorption and bone mineralization in children and has important and largely understudied immunomodulatory effects. Vitamin D deficiency is common in the United States, and there is consensus among treatment providers that levels (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 18, 2018 Category: Hematology Authors: Gregory Wallace, Sonata Jodele, Kasiani C. Myers, Christopher E. Dandoy, Javier El-Bietar, Adam Nelson, Ashley Teusink-Cross, Pooja Khandelwal, Cynthia Taggart, Catherine M. Gordon, Stella M. Davies, Jonathan C. Howell Source Type: research

Single Ultra-High Dose Cholecalciferol to Prevent Vitamin D Deficiency in Pediatric Hematopoietic Stem Cell Transplantation
• Ultra-high dose vitamin D provided prior to transplantation provides an effective means of vitamin D replacement• Normal levels of vitamin D were sustained for up to 8 weeks after administration• Ultra-high dose vitamin D administration resulted in no adverse safety events• Additional inve stigation of outcomes of transplantation following ultra-high dose vitamin D are ongoing (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 18, 2018 Category: Hematology Authors: Gregory Wallace, Sonata Jodele, Kasiani C. Myers, Christopher E. Dandoy, Javier El-Bietar, Adam Nelson, Ashley Teusink-Cross, Pooja Khandelwal, Cynthia Taggart, Catherine M. Gordon, Stella M. Davies, Jonathan C. Howell Source Type: research

Antibiotic Exposure before Respiratory Viral Infection Is Associated with Progression to Lower Respiratory Tract Disease in Allogeneic Hematopoietic Cell Transplant Recipients
Prophylactic and empiric antibiotic use are part of standard care for high-risk patients, especially hematopoietic cell transplant (HCT) recipients, and reduce the risk of morbidity and mortality associated with life-threatening bacterial infections [1-4]. On the other hand, emerging data suggest that antibiotic exposure can affect other adverse transplant outcomes [5-7]. Although the exact mechanism remains elusive, the immunomodulatory effects of antibiotics via altered gut microbiota on the susceptibility to bacterial infection or graft-versus-host disease (GVHD) may be a plausible explanation [6,8-13]. (Source: Biology...
Source: Biology of Blood and Marrow Transplantation - May 17, 2018 Category: Hematology Authors: Chikara Ogimi, Elizabeth M. Krantz, Jonathan L. Golob, Alpana Waghmare, Catherine Liu, Wendy M. Leisenring, Christopher R. Woodard, Sara Marquis, Jane M. Kuypers, Keith R. Jerome, Steven A. Pergam, David N. Fredricks, Mohamed L. Sorror, Janet A. Englund, Source Type: research

Antibiotic Exposure Prior to Respiratory Viral Infection is Associated with Progression to Lower Respiratory Tract Disease in Allogeneic Hematopoietic Cell Transplant Recipients
• We studied effect of antibiotic exposure on respiratory virus disease post-transplant.• Antibiotic exposure pre- and post-transplant was common before viral onset.• Cumulative antibiotic exposure was a risk factor for respiratory disease progression. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 17, 2018 Category: Hematology Authors: Chikara Ogimi, Elizabeth M. Krantz, Jonathan L. Golob, Alpana Waghmare, Catherine Liu, Wendy M. Leisenring, Christopher R. Woodard, Sara Marquis, Jane M. Kuypers, Keith R. Jerome, Steven A. Pergam, David N. Fredricks, Mohamed L. Sorror, Janet A. Englund, Source Type: research

Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic-Cell Transplantation: a Systematic Review and Meta-Analysis
• Antiviral prophylaxis significantly reduces CMV disease and infection• Ganciclovir and letermovir appear to be the best options for CMV outcomes• Inconclusive results of antiviral prophylaxis and survival• Randomized head-to-head comparisons are needed (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 17, 2018 Category: Hematology Authors: Nico Gagelmann, Per Ljungman, Jan Styczynski, Nicolaus Kr öger Source Type: research

A Couple-Based Communication Intervention for Hematopoietic Cell Transplantation Survivors and Their Caregiving Partners: Feasibility, Acceptability, and Change in Process Measures
Cancer and its treatment impact not just patients but also significant others. For married or partnered patients, the spouse/partner is typically the primary caregiver and most important confidante [1]. Effective communication, specifically the ability to express illness-related thoughts and feelings to one's partner and to feel understood, is central to the functioning of both individuals and the couple as a whole [2]. Indeed, several studies have demonstrated that open, supportive discussions about cancer-related concerns (those characterized by self-disclosure and partner responsiveness) are adaptive [3-6], whereas inte...
Source: Biology of Blood and Marrow Transplantation - May 14, 2018 Category: Hematology Authors: Shelby Langer, Laura Porter, Joan Romano, Michael Todd, Stephanie Lee Source Type: research

Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience
Chimeric antigen receptor (CAR)-modified T cells targeting CD19 are under investigation for multiply relapsed or refractory CD19+  acute lymphoblastic leukemia (ALL) [1-5]. Because of unprecedented results, multisite trials conducted at centers throughout the United States and the world led to approval by the US Food and Drug Administration of the first CAR T cell product, tisagenlecleucel (formerly CTL019), in August 2017. This patient population has often already had significant exposure to potentially cardiotoxic agents, such as anthracycline treatment or total body irradiation (TBI), before receipt of CAR T cell...
Source: Biology of Blood and Marrow Transplantation - May 14, 2018 Category: Hematology Authors: Danielle Burstein, Shannon Maude, Stephen Grupp, Heather Griffis, Joseph Rossano, Kimberly Lin Source Type: research

Allogeneic Stem Cell Transplantation From HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International-BFM Studies: Impact of Disease Risk on Outcomes.
Allogeneic HSCT is beneficial for pediatric patients with relapsed or (very) high-risk ALL in remission. A total of 1115 consecutive patients were included in the ALL SCT 2003 BFM study and the ALL SCT 2007-International study and were stratified according to relapse risk (Standard vs. High vs. Very High Risk of Relapse) and donor type (Matched Sibling vs. Matched Donor vs. Mismatched Donor). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 14, 2018 Category: Hematology Authors: Jean-Hugues Dalle, Adriana Balduzzi, Peter Bader, Arjan Lankester, Isaac Yaniv, Jacek Wachowiak, Anna Pieczonka, Marc Bierings, Akif Yesilipek, Petr Sedlacek, Marianne Ifversen, Sabina Sufliarska, Jacek Toporski, Evgenia Glogova, Ulrike Poetschger, Christ Source Type: research

A Couple-Based Communication Intervention for Hematopoietic Cell Transplant Survivors and Their Caregiving Partners: Feasibility, Acceptability, and Change in Process Measures
• A couple-based communication intervention was determined to be feasible• Eighty-seven percent of couples completed all five sessions• Hematopoietic cell transplant patients and partners perceived the program as useful (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 14, 2018 Category: Hematology Authors: Shelby Langer, Laura Porter, Joan Romano, Michael Todd, Stephanie Lee Source Type: research

Cardiac Profile of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Children: a Single Institution Experience
• This is the first study to describe the cardiovascular effects of pediatric CD19 CAR T-cell therapy.• Although 10% had new systolic dysfunction after treatment, persistent dysfunction was rare.• Pre-treatment blast count> 25% or pre-existing cardiac dysfunction warrant close observation. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 14, 2018 Category: Hematology Authors: Danielle Burstein, Shannon Maude, Stephen Grupp, Heather Griffis, Joseph Rossano, Kimberly Lin Source Type: research